Archiwum zagraniczne East News 2023-12
  • 30,00 EUR

    Making print for private purpose, storage in computer memory, no distribution rights.

  • 40,00 EUR

    Strictly for editorial, single use on a personal (nonprofit) web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.

  • 75,00 EUR

    Strictly for editorial, single use on a commercial web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.

  • 90,00 EUR

    Strictly for editorial, single use, inside of newspaper, magazine, book (including digital version), one edition, one single country. Not for resale.

Gross prices
Contact us to calculate price for another use. Prices only for online sales.
<TAB><TAB><TAB>100432+0900 JAPAN OUT
A photo shows Lecanemab, sold under the brand name Leqembi, at a hospital in Itabashi Ward, Tokyo on December 25, 2023. Lecanemab is a monoclonal antibody medication used for the treatment of Alzheimer's disease. The drug was developed by Eisai and Biogen and subsequently approved in the United States and Japan.( The Yomiuri Shimbun via AP Images )
More >><< Less
Archiwum zagraniczne East News 2023-12
2023-12-25
Kota Kiriyama/Associated Press/East News
Associated Press
Kota Kiriyama
23359147024070
2,85MB
42cm x 29cm by 300dpi
2023, 25, A, ALZHEIMER, AND, ANTIBODY, AP, APPROVED, AT, BIOGEN, BRAND, BY, CTR, DECEMBER, DEVELOPED, DISEASE, DRUG, EISAI, FIN, FINANCE, FOR, HEALTH, HOSPITAL, HTH, IMAGES, IN, IS, ITABASHI, JAPAN, JPN, KIRIYAMA, KOTA, lecanemab, leqembi, LIF, LIFE, LIFESTYLE, MEDICATION, MEDICINE, MONOCLONAL, NAME, OF, ON, PHOTO, S, SCI, SCIENCE, SHIMBUN, SHOWS, SOLD, STATES, SUBSEQUENTLY, THE, TOKYO, TREATMENT, UNDER, UNITED, USED, VIA, WARD, WAS, YOMIURI,